MR
Merus
MRUS · NASDAQ
$90.00 +0.00% (+$0.00)
Market Cap $6.83B
P/E Ratio -
Div. Yield -
ROE 48.76%
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 10.32x
P/S 133.38x
EV/FFO N/A
Growth
80 /100
Growing Book val. growth 23.46%
Rev. growth 11.85%
FCF growth N/A
Profitability
0 /100
Weak Net margin 654.44%
Op. margin 648.06%
FCF margin 621.16%
Quality
1 /100
Poor ROE 48.76%
ROA 43.38%
Asset turnover 0.07x
Debt
95 /100
Low Current ratio 7.97x
Net debt/EBITDA 0.94x
Debt/Equity 0.02x
Stability
30 /100
Unstable Rev. volatility 50.15%
EPS volatility 55.37%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MRUS
Online
About the company
Merus N.V. is a Dutch biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company is particularly known for its bispecific antibody technology, designed to selectively activate the immune system against cancer cells. Merus N.V. concentrates on developing treatments that can offer new hope to patients suffering from various types of cancer, including those who have failed other therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Jan van de Winkel
Employees
260
Headquarters
Utrecht